Skip to content
Ventavis(iloprost)
Ventavis (iloprost) is a small molecule pharmaceutical. Iloprost was first approved as Ventavis on 2003-09-15. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against prostacyclin receptor. In addition, it is known to target prostaglandin E2 receptor EP4 subtype, prostaglandin E2 receptor EP2 subtype, prostaglandin E2 receptor EP3 subtype, prostaglandin D2 receptor, thromboxane A2 receptor, prostaglandin F2-alpha receptor, and prostaglandin E2 receptor EP1 subtype.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Ventavis
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iloprost
Tradename
Company
Number
Date
Products
VENTAVISActelionN-021779 RX2005-12-08
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ventavisNew Drug Application2021-03-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pulmonary hypertensionEFO_0001361D006976I27.20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC11: Iloprost
HCPCS
Code
Description
Q4074
Iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms
Clinical
Clinical Trials
84 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary hypertensionD006976EFO_0001361I27.20211721231
Pulmonary arterial hypertensionD0000810291341816
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9—3—126
Peripheral arterial diseaseD058729EFO_0004265———112
HypertensionD006973EFO_0000537I10———1—1
Heart failureD006333EFO_0003144I50———1—1
SarcoidosisD012507EFO_0000690D80-D89———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Respiratory distress syndromeD012128EFO_1000637J80221—15
Systemic sclerodermaD012595EFO_0000717M34—22——4
Septic shockD012772A48.3—22——3
Pulmonary fibrosisD011658J84.10—21——2
Chronic renal insufficiencyD051436N18—11——1
Balloon angioplasty coronaryD015906EFO_0003951—11——1
Coronary angiographyD017023—11——1
Raynaud diseaseD011928EFO_1001145I73.0——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.9012——36
Respiratory insufficiencyD012131HP_0002093J96.913———3
Congenital heart defectsD006330HP_0001627Q24.911——12
Covid-19D000086382U07.1—2———2
ArteriosclerosisD001161EFO_0009086I70—1———1
Arterial occlusive diseasesD001157EFO_0009085—1———1
PneumoniaD011014EFO_0003106J18—1———1
Healthy volunteers/patients—11———1
Shoulder fracturesD012784S42.911———1
Multiple organ failureD009102EFO_1001373—1———1
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute lung injuryD055371EFO_00046101————1
AsthmaD001249EFO_0000270J451————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Eisenmenger complexD004541I27.83————11
Coronary artery diseaseD003324I25.1————11
Pulmonary infarctionD054060EFO_1001408————11
Type 2 diabetes mellitusD003924EFO_0001360E11————11
Video-assisted thoracic surgeryD020775————11
PregnancyD011247EFO_0002950Z33.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameILOPROST
INNiloprost
Description
Iloprost is a carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension. It has a role as a platelet aggregation inhibitor and a vasodilator agent. It is a monocarboxylic acid, a secondary alcohol and a carbobicyclic compound.
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O
Identifiers
PDB—
CAS-ID78919-13-8
RxCUI—
ChEMBL IDCHEMBL494
ChEBI ID63916
PubChem CID5311181
DrugBankDB01088
UNII IDJED5K35YGL (ChemIDplus, GSRS)
Target
Agency Approved
PTGIR
PTGIR
Organism
Homo sapiens
Gene name
PTGIR
Gene synonyms
PRIPR
NCBI Gene ID
5739
Protein name
prostacyclin receptor
Protein synonyms
PGI receptor, PGI2 receptor, prostaglandin I2 (prostacyclin) receptor (IP), Prostaglandin I2 receptor, Prostanoid IP receptor
Uniprot ID
P43119
Mouse ortholog
Ptgir (19222)
prostacyclin receptor (Q52KE5)
Alternate
PTGER4
PTGER4
PTGER2
PTGER2
PTGER3
PTGER3
PTGDR
PTGDR
TBXA2R
TBXA2R
PTGFR
PTGFR
PTGER1
PTGER1
Organism
Homo sapiens
Gene name
PTGER4
Gene synonyms
PTGER2
NCBI Gene ID
5734
Protein name
prostaglandin E2 receptor EP4 subtype
Protein synonyms
PGE receptor, EP4 subtype, PGE2 receptor EP4 subtype, prostaglandin E receptor 4 (subtype EP4), Prostanoid EP4 receptor
Uniprot ID
Q3MJ87
Mouse ortholog
Ptger4 (19219)
prostaglandin E2 receptor EP4 subtype (P32240)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,853 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,131 adverse events reported
View more details